Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario? - PubMed
a day ago
- #immunotherapy
- #liver metastases
- #urothelial carcinoma
- Liver metastases in advanced urothelial carcinoma (mUC) are a poor prognostic factor.
- Two cohorts were analyzed: pembrolizumab post-platinum therapy (n=1,341) and avelumab maintenance (n=291).
- Median OS was significantly lower in patients with liver metastases (9.4 vs. 20.1 months for pembrolizumab; 16.4 vs. 27.0 months for avelumab).
- Better ECOG-PS and higher BMI (≥25 kg/m²) were associated with improved survival in both cohorts.
- Pembrolizumab and avelumab showed improved outcomes compared to historical chemotherapy data.
- The study highlights the need for personalized treatment strategies in high-risk subgroups.